Altria Group extends $3 billion credit agreement by one year to 2029

Published 23/07/2025, 23:14
© Reuters

Altria Group , Inc. (NYSE:MO), a $100 billion market cap company with a "GREAT" financial health rating according to InvestingPro, announced Wednesday that it has entered into an extension agreement to amend its $3.0 billion senior unsecured five-year revolving credit agreement. The agreement, originally dated October 24, 2023, was made with JPMorgan Chase (NYSE:JPM) Bank, N.A. and Citibank, N.A. as administrative agents, along with a group of lenders.

According to the company’s press release statement, the extension agreement moves the expiration date of the credit facility from October 24, 2028, to October 24, 2029. All other terms and conditions of the original credit agreement remain unchanged. The company maintains a moderate debt level while offering shareholders a substantial 6.83% dividend yield, having maintained dividend payments for 55 consecutive years.

The lenders involved in the agreement and their affiliates have existing relationships with Altria and its subsidiaries, including the provision of financial services such as cash management, investment banking, and trust services.

This information is based on a filing with the U.S. Securities and Exchange Commission.

In other recent news, Altria Group has been in the spotlight due to several significant developments. The company announced a temporary suspension of trading under its employee benefit plans. This move is linked to a transition in trustee services from State Street (NYSE:STT) Bank and Trust Company to Fidelity Management Trust Company, affecting Deferred Profit-Sharing Plans for both salaried and hourly employees. Additionally, UBS upgraded Altria’s stock rating from Sell to Neutral, citing a positive outlook due to increased enforcement against illicit vape products. UBS highlighted a decline in vapor product exports from China to the U.S. as a contributing factor. On the other hand, Jefferies initiated coverage on Altria with an Underperform rating, expressing concerns about risks to Altria’s U.S. combustibles business. In a broader industry context, the FDA authorized Juul Labs’ e-cigarettes to remain on the U.S. market, while a joint operation by the FDA and U.S. Customs and Border Protection led to the seizure of nearly two million units of unauthorized e-cigarette products worth $33.8 million. These recent developments reflect ongoing regulatory and market dynamics impacting Altria and the tobacco industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.